Cart (0 Items)
Your cart is currently empty.
View ProductsTovetumab Biosimilar – Anti-PDGFRA , PDGFR2, CD140a mAb – Research Grade
| Size | |
|---|---|
| Brand | |
| Product type | |
| Clonality | |
| Expression system | |
| Applications |
| Product name | Tovetumab Biosimilar - Anti-PDGFRA , PDGFR2, CD140a mAb - Research Grade |
|---|---|
| Source | CAS 1243266-04-7 |
| Species | Homo sapiens |
| Expression system | Mammalian cells |
| Purity | >85% |
| Buffer | PBS buffer PH7.5 |
| Delivery condition | Blue ice (+4°C) |
| Delivery Time | 3-5 days if in stock; 3-5 weeks if production needed |
| Storage condition | store at -80°C |
| Brand | ProteoGenix |
| Applications | ELISA,WB |
| Aliases /Synonyms | Tovetumab,MEDI-575,PDGFRA , PDGFR2, CD140a,anti-PDGFRA , PDGFR2, CD140a |
| Reference | PX-TA1328 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype | IgG2-kappa |
| Clonality | Monoclonal Antibody |
Description of Tovetumab Biosimilar - Anti-PDGFRA / PDGFR2/ CD140a mAb - Research Grade
General information on Anti-PDGFRA / PDGFR2/ CD140a[Homo sapiens] (Tovetumab) Monoclonal Antibody
Tovetumab has been investigated for the treatment of Cancer, Glioblastoma Multiforme, and Advanced Solid Malignancies.
Related products
Antigen
Platelet Derived Growth Factor proteins Receptor Alpha
PX-P5106 385€
SIL
Stable Isotope Labelled Tovetumab Biosimilar – Anti-PDGFRA / PDGFR2/ CD140a mAb – Research Grade
PX-TA1328-SIL 15000€
ELISA
Reviews
Il n’y a pas encore d’avis.